Drugs /

pf-06873600

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally bioavailable, cyclin dependent kinase (CDK) inhibitor, with potential antineoplastic activity. Upon administration, ebvaciclib selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and proliferation and are frequently overexpressed in tumor cells.

Clinical Trials

View Clinical Trials for pf-06873600

Pf-06873600 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating pf-06873600, 1 is phase 2 (1 open).

ER Expression, ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for pf-06873600 clinical trials.

Breast carcinoma, fallopian tube carcinoma, and ovarian carcinoma are the most common diseases being investigated in pf-06873600 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pf-06873600
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pf-06873600 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ebvaciclib, cdk inhibitor pf-06873600, pf 06873600, cyclin-dependent kinase inhibitor pf-06873600
Drug Categories [2]:
CDK inhibitors, Serine/threonine kinase inhibitors
Drug Target(s) [2]:
CDK2, CDK4, CDK6
NCIT ID [1]:
C151988

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.